Skip to main content
. 2019 May 21;6(2):213–225. doi: 10.3233/JND-180351

Fig.4.

Fig.4

Derivation of CINRG DNHS cohorts for comparison of eteplirsen studies. The CINRG DNHS database contains data from 440 patients with DMD across all ages. The All CINRG DNHS cohort (n = 172) comprised glucocorticoid-treated patients with FVC% p assessments obtained between the ages of 10 and 18 years, and excluded any known exon 44 skip–amenable patients. The Genotyped CINRG DNHS cohort (n = 148) comprised glucocorticoid-treated, genetically confirmed patients with FVC% p assessments between the ages of 10 and 18 years and excluded exon 44 skip-amenable patients. The Exon 51 CINRG DNHS cohort (n = 20) comprised glucocorticoid-treated patients between the ages of 10 and 18 years with mutations amenable to exon 51 skipping. CINRG DNHS, Cooperative International Neuromuscular Research Group Duchenne Natural History Study; FVC% p, percent predicted forced vital capacity; GC, glucocorticoid. Dashed box represents pre-specified comparator.